- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02672306
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease (SEESUPAD)
April 25, 2018 updated by: South China Research Center for Stem Cell and Regenerative Medicine
Clinical Study on the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to evaluate the safety and the efficacy of (Human Umbilical Cord-Derived Mesenchymal Stem Cells) UCMSCs for patients with Alzheimer's disease (AD).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Randomized, Safety/ Efficacy Study Official Title: Multicenter, Randomized, Double-blind, Placebo Controlled Trial of UCMSCs in Subjects With Alzheimer's Disease
Study Type
Interventional
Enrollment (Anticipated)
16
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510320
- South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 50 to 80, male and female.
- A diagnosis of probable AD and Mixed Dementia according to the criteria of the NINCDS-ADRDA
- Treatment with other cholinesterase inhibitors, such as a stable dose of donnepiazide tablets (5mg/ day or 10mg/ day) or the use of heavy tartaric acid karbalin capsules, is currently being used.
- MMSE score between 10 and 26.
- Voluntarily participating subject who sign the Inform Concent
Exclusion Criteria:
- Caused by other reasons of dementia (vascular dementia, infectious disease of the central nervous system (such as HIV, syphilitic dementia), g - she's disease, Parkinson's disease, Lou gehrig's disease, huntington's disease DLB, traumatic brain dementia, other physical and chemical factors (such as: drug poisoning, alcoholism, carbon monoxide poisoning and other dementia), important body disease (such as hepatic encephalopathy, pulmonary encephalopathy dementia), intracranial placeholder lesions, endocrine system disease, such as thyroid disease, parathyroid disease), and vitamins and other causes of dementia)
- The Hamilton depression scale (HAMD) score > 17, or patients with a history of depression or other psychiatric or psychiatric disorders.
- The Hachinski ischemic index scale (HIS) scored > 4.
- The brief intelligence status examination scale (MMSE) score of 10 patients.
- Liver function (ALT, AST) exceeded the normal range limit of 1.5 times, SCr exceeded normal range upper limit, white blood cell count < 4.0 x 109/L or platelet < 100 x 109/L, hemoglobin < 100g/L.
- Patients with type 1 diabetes, obstructive pulmonary disease (copd) or asthma, vitamin B12 or folate deficiency patients, not control good digestion, liver, kidney, endocrine and cardiovascular system diseases (especially sick sinus syndrome and conduction block), patients with HIV/AIDS, syphilis, active tuberculosis, etc.
- A person with cancer or a history of cancer.
- People with a clinically significant history of stroke, who have had a seizure or a head injury in the past two years, have caused the disorder.
- There is a history of congestive heart failure or a history of myocardial infarction, and a blood disease in two years.
- Drug clinical trials were performed within 3 months of screening.
- Anti-ad agents are being used in addition to the programme requirements.
- The use of stem cell therapy in half a year.
- People with history of alcoholism and substance abuse, allergies, or history of allergies.
- Patients who had been hospitalized for more than 3 months before screening. of allergies.
- The researchers think it is inappropriate to participate in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UCMSCs
Subjects with Alzheimer's Disease Intervention: UCMSCs
|
Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
Other Names:
|
Placebo Comparator: Placebo
Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
|
Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
Time Frame: 36 weeks from post-administration
|
A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.
|
36 weeks from post-administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
Time Frame: 10 weeks,18 weeks,24 weeks,48weeks from post-administration
|
A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.
|
10 weeks,18 weeks,24 weeks,48weeks from post-administration
|
Change in Mini-Mental State Examination (MMSE) Score
Time Frame: 10 weeks,18 weeks,36 weeks,24 weeks,48weeks from post-administration
|
A frequently used screening instrument for Alzheimer's disease drug studies.
It evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons.
|
10 weeks,18 weeks,36 weeks,24 weeks,48weeks from post-administration
|
Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score
Time Frame: 10 weeks,18 weeks,24 weeks,36 weeks,48weeks from post-administration
|
10 weeks,18 weeks,24 weeks,36 weeks,48weeks from post-administration
|
|
Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score
Time Frame: 10 weeks,18 weeks,24 weeks,36 weeks,48weeks from post-administration
|
ADCS-ADL assesses functional performance in subjects with Alzheimer's disease.
In a structured interview format, informants are queried as to whether subjects attempted each item in the inventory during the prior 4 weeks and their level of performance.
The ADCS-ADL scale discriminates well between normal controls and mild AD patients.
It has good test-retest reliability.
The ADCS-ADL includes some items from traditional basic ADL scales (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as items from instrumental activities of daily living scales (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading).
|
10 weeks,18 weeks,24 weeks,36 weeks,48weeks from post-administration
|
Change in Neuropsychiatric Inventory (NPI) Score
Time Frame: 10 weeks,18 weeks,24 weeks,36 weeks,48weeks from post-administration
|
The NPI is a well-validated, reliable, multi-item instrument to assess psychopathology and behavior in AD based on interview with the informant.
|
10 weeks,18 weeks,24 weeks,36 weeks,48weeks from post-administration
|
Changes in AD Biomarkers
Time Frame: 36 weeks from post-administration
|
Plasma beta-amyloid proteins will be collected from blood samples obtained.
|
36 weeks from post-administration
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptoms Checklist and Adverse Event Assessment
Time Frame: From Day0(administration)to 48 weeks post-administration.
|
Adverse events and symptoms checklist are used to monitor signs or symptoms that may or may not be related to study medication, abnormalities detected during physical examination, or clinical significant laboratory abnormalities.
|
From Day0(administration)to 48 weeks post-administration.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2017
Primary Completion (Anticipated)
October 1, 2018
Study Completion (Anticipated)
October 1, 2019
Study Registration Dates
First Submitted
January 24, 2016
First Submitted That Met QC Criteria
January 29, 2016
First Posted (Estimate)
February 3, 2016
Study Record Updates
Last Update Posted (Actual)
April 26, 2018
Last Update Submitted That Met QC Criteria
April 25, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCMSC-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on UCMSCs
-
Yantai Yuhuangding HospitalRecruiting
-
South China Research Center for Stem Cell and Regenerative...Guangzhou Panyu Central HospitalUnknownFracture | Bone Nonunion
-
China Medical University HospitalUnknownBronchopulmonary Dysplasia | Extremely Premature Infants | Severe BPD That Conventional Therapies Has Failed | No Severe Congenital Anomalies | no Severe IVH Neither Cystic PVLTaiwan
-
Yantai Yuhuangding HospitalRecruiting
-
Joshua M HareThe Marcus FoundationTerminatedMetabolic Syndrome | Endothelial Dysfunction | Chronic InflammationUnited States
-
Guangdong Provincial Hospital of Traditional Chinese...Peking Union Medical College HospitalNot yet recruitingPsoriasis | Drug Effect | Drug Toxicity | Mesenchymal Stromal CellsChina
-
Joshua M HareWithdrawnCOVID-19 | Acute Respiratory Distress Syndrome | Corona Virus Infection
-
Sun Yat-sen UniversityUnknownAcute Respiratory Distress SyndromeChina
-
Smt. Kashibai Navale Medical College and General...CompletedType 2 Diabetes | Vitamin B12 Deficiency | HyperhomocysteinemiaIndia